MX360515B - Proceso para la reduccion y/o remocion del factor de coagulacion xi y factor de coagulacion xi activado de soluciones que contienen tales factores de coagulacion. - Google Patents

Proceso para la reduccion y/o remocion del factor de coagulacion xi y factor de coagulacion xi activado de soluciones que contienen tales factores de coagulacion.

Info

Publication number
MX360515B
MX360515B MX2013005384A MX2013005384A MX360515B MX 360515 B MX360515 B MX 360515B MX 2013005384 A MX2013005384 A MX 2013005384A MX 2013005384 A MX2013005384 A MX 2013005384A MX 360515 B MX360515 B MX 360515B
Authority
MX
Mexico
Prior art keywords
fxia
fxi
removal
reduction
coagulation factors
Prior art date
Application number
MX2013005384A
Other languages
English (en)
Other versions
MX2013005384A (es
Inventor
Winge Stefan
Schulz Petra
Gruber Gerhard
Bal Frederic
Marks Frank
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43618292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360515(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of MX2013005384A publication Critical patent/MX2013005384A/es
Publication of MX360515B publication Critical patent/MX360515B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

La presente invención se refiere a un proceso para la reducción y/o remoción de FXI y FXIa de una solución de fuente que contiene tales factores de coagulación e inmunoglobulinas como componentes principales, que comprenden las siguientes etapas: a) poner en contacto la solución que contiene FXI y/o FXIa con un gel cromatográfico de afinidad en donde la heparina o heparán se enlaza al material de matriz; b) permitir la adsorción de FXI y/o FXIa y c) separación del líquido agotado de FXI y/o FXIa del medio de adsorción.
MX2013005384A 2010-11-16 2011-11-16 Proceso para la reduccion y/o remocion del factor de coagulacion xi y factor de coagulacion xi activado de soluciones que contienen tales factores de coagulacion. MX360515B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10191398 2010-11-16
PCT/EP2011/070257 WO2012066036A1 (en) 2010-11-16 2011-11-16 A PROCESS FOR REDUCTION AND/OR REMOVAL OF FXI AND FXIa FROM SOLUTIONS CONTAINING SAID COAGULATION FACTORS

Publications (2)

Publication Number Publication Date
MX2013005384A MX2013005384A (es) 2013-07-29
MX360515B true MX360515B (es) 2018-11-07

Family

ID=43618292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005384A MX360515B (es) 2010-11-16 2011-11-16 Proceso para la reduccion y/o remocion del factor de coagulacion xi y factor de coagulacion xi activado de soluciones que contienen tales factores de coagulacion.

Country Status (13)

Country Link
US (1) US20140051839A1 (es)
EP (1) EP2640413B1 (es)
JP (1) JP2014501721A (es)
KR (1) KR20130124507A (es)
CN (2) CN106928344A (es)
AU (1) AU2011331208B2 (es)
BR (1) BR112013011277A2 (es)
CA (1) CA2817096A1 (es)
ES (1) ES2743711T3 (es)
IL (1) IL225878A0 (es)
MX (1) MX360515B (es)
RU (1) RU2649363C2 (es)
WO (1) WO2012066036A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522354B1 (en) 2011-05-12 2017-08-23 CSL Behring GmbH Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins
CN103087184B (zh) * 2013-01-14 2014-04-02 山西康宝生物制品股份有限公司 人血白蛋白制品中激肽释放酶原激活剂的控制方法
SG11201705982PA (en) * 2015-01-23 2017-08-30 Helix Biopharma Corp Antibody-urease conjugates for therapeutic purposes
CN119881293A (zh) * 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP3590528A1 (en) * 2018-07-06 2020-01-08 Octapharma AG Fx activation process and its use in the preparation of a fxa composition
CN109456407B (zh) * 2018-10-26 2022-02-18 山东泰邦生物制品有限公司 一种血浆人免疫球蛋白的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
DK2102335T3 (da) * 2007-01-04 2012-05-07 Crucell Holland Bv Rensning af faktor XI
UA85741C2 (ru) * 2007-02-27 2009-02-25 Костянтин Васильевич Курищук Способ получения иммуноглобулина
EP2522354B1 (en) 2011-05-12 2017-08-23 CSL Behring GmbH Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins

Also Published As

Publication number Publication date
CN103328000A (zh) 2013-09-25
CN106928344A (zh) 2017-07-07
CA2817096A1 (en) 2012-05-24
EP2640413A1 (en) 2013-09-25
ES2743711T3 (es) 2020-02-20
KR20130124507A (ko) 2013-11-14
JP2014501721A (ja) 2014-01-23
EP2640413B1 (en) 2019-06-12
IL225878A0 (en) 2013-06-27
WO2012066036A1 (en) 2012-05-24
BR112013011277A2 (pt) 2016-11-01
MX2013005384A (es) 2013-07-29
AU2011331208B2 (en) 2016-12-01
AU2011331208A1 (en) 2013-05-23
RU2013127275A (ru) 2014-12-27
US20140051839A1 (en) 2014-02-20
RU2649363C2 (ru) 2018-04-02

Similar Documents

Publication Publication Date Title
NZ603616A (en) Apparatus and process of purification of proteins
MX2013005384A (es) Proceso para la reduccion y/o remocion del factor de coagulacion xi y factor de coagulacion xi activado de soluciones que contienen tales factores de coagulacion.
SG10201804869UA (en) Purification of biological molecules
MX344268B (es) Proceso para purificacion de proteinas.
MX371091B (es) Sorbentes para la eliminacion de mercurio.
EP4545964A3 (en) Chromatographic isolation of cells and other complex biological materials
MX2016001601A (es) Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
WO2013036863A3 (en) Efficient use of ionic liquids
BR112013007131A2 (pt) aparelho e método de purificação do fluxo de gás
MY180931A (en) Gas separation composite membrane, gas separation module, gas separation apparatus, gas separation method, and method of producing gas separation composite membrane
MY170308A (en) Alcohol production method
MY177824A (en) A process and system for removing halogen compounds
WO2014129964A3 (en) Chromatographic purification of virus preparations with negatively charged particles
EA201491246A1 (ru) Способ облагораживания газа
WO2014012115A3 (en) Method for inducing cells to less mature state
MY163269A (en) Composite media for water treatment processes and methods of using same
WO2012134186A3 (en) Adsorbents for the recovery of catalyst from block co-polymer process and method for regenerating of the same
MX2019009336A (es) Metodo de procesamiento combinado para soluciones que contienen litio.
MX2012013026A (es) Metodo cromatografico de interaccion hidrofoba.
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
WO2012121495A3 (ko) 폴리케톤 중합 반응폐액으로부터 귀금속을 회수하는 방법
MY160083A (en) A method for isolating shikimic acid from oil palm waste
GR1007341B (el) Διαγνωστικος προσδιορισμος
IN2012DN01382A (es)
WO2012015219A3 (en) Real-time monitoring of depletion of high-abundance blood proteins or recovery of low-abundance blood proteins by uv spectrometry

Legal Events

Date Code Title Description
FG Grant or registration